Edwards Lifesciences' third quarter EPS of $0.80 beat estimates while company raised 2026 guidance

Edwards Lifesciences reported third quarter results that surpassed consensus expectations for both revenue and earnings, driven by resilient demand in its core TAVR segment and a 45.6% surge in its TMTT portfolio. Following the strong performance, management raised its full-year 2026 outlook for total sales, TAVR product growth, and adjusted earnings per share.

Key Highlights

• TAVR revenue reached $1.24 billion, growing 8.8% on a constant currency basis and exceeding the consensus estimate of $1.15 billion.
• Transcatheter Mitral and Tricuspid Therapies (TMTT) sales grew 45.6% year-over-year to $207 million, supported by rapid adoption of the PASCAL and EVOQUE systems.
• Full-year 2026 sales growth guidance was increased to approximately 11.5%, up from the previous range of 10% to 11%.
• Management raised its full-year adjusted EPS guidance to $2.97–$3.05, representing 18% year-over-year growth at the midpoint.